WeVote
Log In

Bill

Bill

S 5314

Establishes patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurer-designated pharmacy

2025 Regular Session Introduced by Jamaal Bailey

Establishes safety and quality standards for distributing patient-specific medications through insurer-designated pharmacies, protecting patients and ensuring proper dispensing.

REFERRED TO INSURANCE
0
WeVote Research Nonpartisan
Bill Summary · S 5314

Summary of Bill S 5314

Overview

  • Bill Number: S 5314
  • Title: Establishes patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurer-designated pharmacy
  • Status: Referred to Insurance
  • Introduced: February 20, 2025
  • Primary Sponsor: Jamaal Bailey

Purpose and Intent

The bill aims to ensure patient safety and enhance quality assurance in the distribution of patient-specific medications that are dispensed through pharmacies designated by insurers. The exact mechanisms, standards, and enforcement details are not included in the available summary, but the title indicates a focus on safety, quality control, and oversight of the distribution process.

Key Provisions (as indicated by summary)

  • The text provided does not include the specific provisions. Based on the bill’s title, anticipated areas might include:
    • Establishing safety and quality standards for distributing patient-specific medications
    • Defining roles and responsibilities of the insurer-designated pharmacy
    • Establishing verification, handling, and dispensing procedures
    • Implementing reporting, auditing, or compliance review requirements
    • Setting enforcement mechanisms or penalties for noncompliance
    • Clarifying definitions (e.g., what constitutes “patient-specific medication”)
  • Note: The exact statutory language, definitions, timelines, and any cost, funding, or implementation provisions are not available in the provided content.

Affected Parties

  • Patients receiving patient-specific medications through insurer-designated pharmacies
  • Insurers that designate or contract with pharmacies for patient-specific medications
  • Insurer-designated pharmacies and their staff
  • Healthcare providers involved in prescribing or coordinating patient-specific therapies

Legislative History and Status

  • Introduced on February 20, 2025
  • Referred to the Senate Committee on Insurance (INDICATED: “REFERRED TO INSURANCE”)
  • No additional actions listed in the provided material beyond the initial referral
  • Related bills (prior-session or companion): S 7252, S 7413, A 1720 (companion); S 7252 and S 7413 are prior-session Senate bills, and A 1720 is a companion in the Assembly

Sponsorship

  • Primary Sponsor: Jamaal Bailey

Related Legislation

  • S 7252 (prior-session)
  • S 7413 (prior-session)
  • A 1720 (companion)

Timeline and Next Steps

  • As of the provided information, the bill is awaiting action in the Senate Insurance Committee after its referral.
  • If advanced, it would proceed through committee hearings, potential amendments, and votes before moving to higher chambers (as per the state’s legislative process).
  • Watch for: committee reports, fiscal notes (if any), amendments clarifying definitions and enforcement, and any companion actions in the Assembly.

If you’d like, I can refine this once the full bill text or committee memo becomes available, to highlight specific definitions, standards, and compliance timelines.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.